Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

First US product approval for Taiho Oncology

This article was originally published in Scrip

Executive Summary

The US FDA has approved Taiho Pharmaceuticals Co. Ltd.'s Lonsurf (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of metastatic colorectal cancer (mCRC). It is the first approval for Taiho's US oncology division. Launch is expected within the next two weeks but Lonsurf's price has yet to be disclosed.

Advertisement

Related Content

VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register